Chaps,
I've been on Cardarine (20mg per day) for 3 months solid and absolutely love the compound. I'd like to stay on forever.
What are your experiences with Cardarine?
Post up any lab studies on Cardarine too. I know the carcinogenic angle but that study was on rodents at massive dosages (unpublished unfortunately).
https://spiral.imperial.ac.uk/bitstream/10044/1/65136/7/Dear Editor_V_upload_spirall.pdf
However, there is cause for concern regarding at least one drug that activates PPARβ/δ, GW501516, developed by GlaxoSmithKline plc (GSK) in the early 2000’s. Despite these concerns and although not confirmed in humans, following the publication of endurance exercise studies in rodents, a significant underground market has developed for unlicensed GW501516 (also referred to as Endurobol or Cardarine) in a bid to enhance human athletic performance. Of particular relevance are two abstracts from GSK showing that GW501516 causes cancer in rats (6) and mice (7) after 104 weeks of dosing. Although, neither of these studies has been published as full peer reviewed papers these abstracts have been very influential. The phase 4 trial (NCT00841217) was stopped and warnings issued by the World Anti-Doping Agency(8), Health Canada (9) and most recently in April 2018 GW501516 was classified as a poisonous substance in Australia (10). The precise role of PPARβ/δ in cancer, particularly in humans however remains unclear, as reports continue to emerge showing that agonists may either increase or protect against different cancers(11).
https://academic.oup.com/carcin/article/28/12/2641/2476288/
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines
https://www.sciencedirect.com/science/article/pii/S0300483X08004472
Results from this study demonstrate that two human lung cancer cell lines respond to ligand activation of PPARβ/δ by modulation of target gene expression (Angptl4), but fail to exhibit significant modulation of cell proliferation.
https://clinicaltrials.gov/ct2/show/NCT00841217?term=NCT00841217&rank=1
Essentially, there are no published studies on humans and Cardarine has been removed from trials due to the possibility of proliferation of cancerous cells.
I've been on Cardarine (20mg per day) for 3 months solid and absolutely love the compound. I'd like to stay on forever.
What are your experiences with Cardarine?
Post up any lab studies on Cardarine too. I know the carcinogenic angle but that study was on rodents at massive dosages (unpublished unfortunately).
https://spiral.imperial.ac.uk/bitstream/10044/1/65136/7/Dear Editor_V_upload_spirall.pdf
However, there is cause for concern regarding at least one drug that activates PPARβ/δ, GW501516, developed by GlaxoSmithKline plc (GSK) in the early 2000’s. Despite these concerns and although not confirmed in humans, following the publication of endurance exercise studies in rodents, a significant underground market has developed for unlicensed GW501516 (also referred to as Endurobol or Cardarine) in a bid to enhance human athletic performance. Of particular relevance are two abstracts from GSK showing that GW501516 causes cancer in rats (6) and mice (7) after 104 weeks of dosing. Although, neither of these studies has been published as full peer reviewed papers these abstracts have been very influential. The phase 4 trial (NCT00841217) was stopped and warnings issued by the World Anti-Doping Agency(8), Health Canada (9) and most recently in April 2018 GW501516 was classified as a poisonous substance in Australia (10). The precise role of PPARβ/δ in cancer, particularly in humans however remains unclear, as reports continue to emerge showing that agonists may either increase or protect against different cancers(11).
https://academic.oup.com/carcin/article/28/12/2641/2476288/
Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines
https://www.sciencedirect.com/science/article/pii/S0300483X08004472
Results from this study demonstrate that two human lung cancer cell lines respond to ligand activation of PPARβ/δ by modulation of target gene expression (Angptl4), but fail to exhibit significant modulation of cell proliferation.
https://clinicaltrials.gov/ct2/show/NCT00841217?term=NCT00841217&rank=1
Essentially, there are no published studies on humans and Cardarine has been removed from trials due to the possibility of proliferation of cancerous cells.